A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

Neoplasms Clinical Trial

Official title:

A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04964375
• Other study ID #: ABSK043-101
• Status: Recruiting
• Phase: Phase 1
• Start date: August 31, 2021
• Est. completion date: March 23, 2023

Study information

• Verified date: July 2021
• Source: Abbisko Therapeutics Co, Ltd
• Contact: Ming Zhang
• Phone: +86-21-68912098
• Email: ming.zhang[@]abbisko.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor. Preliminary antitumor activity will also be assessed. Investigate the pharmacodynamics (PD) effects and Investigate the metabolites of oral ABSK043

Description:

The study will start with a dose escalation part of single-agent ABSK043 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK043 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 23, 2023
• Est. primary completion date: October 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient should understand, sign, and date the written voluntary informed consent form prior to screening.

2. Male or female aged 18 years or older (or other age range required by local regulations or IRB).

3. For Escalation part: patients must have histologically confirmed solid tumors that have progressed on or intolerance to standard therapy or whom no standard therapy exists or whom refuse to receive standard therapy;

For Expansion Part:

1. Melanoma cohort: Patients must have histologically confirmed melanoma that have have progressed on or intolerance to standard therapy(including immune-checkpoint inhibitors) or whom no standard therapy exists or whom refuses to receive standard therapy

2. MSI-H/dMMR cohort: Patients must have histologically confirmed solid tumors harboring MSI-H or dMMR that have progressed on or intolerance to standard therapy or whom no standard therapy exists or whom refuses to receive standard therapy.

3. Patients must have at least one measurable target lesion according to RECIST 1.1.

4. Patients are willing to receive biopsy. 4. ECOG performance status 0 or 1 5. Life expectancy =3 months 6. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first

dose of study drug:

1. Absolute neutrophil count (ANC) =1.5×109/L

2. Platelet count (PLT) =75×109/L without transfusions within 14 days before 1st dose

3. Hemoglobin (Hb) =90 g/L

4. Total bilirubin (TBIL) =1.5×ULN

5. Aspartate transaminase (AST)/alanine transaminase (ALT), =3×ULN (=5 × ULN in the presence of hepatic metastases).

6. Serum creatinine (Cr) of =1.5×ULN for the reference laboratory or creatinine clearance (Crcl) =50 mL/min based either on urine collection or Cockcroft-Gault estimation

Exclusion Criteria:

1. Known allergy or hypersensitivity to any component of the investigational product.

2. For expansion part MSI-H or dMMR cohort only: previously treated with PD-(L)1 pathway inhibitors (including monoclonal antibody and small molecular agents).

3. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, etc.

4. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan, history of radiation pneumonitis in the radiation field (fibrosis) is permitted.

5. For expansion part only: Has a known additional malignancy that is progressing or required active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or other in situ cancers.

6. Inability to take oral medication or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication.

7. Previous anti-cancer therapy, including chemotherapy (chemotherapy with nitrosourea or mitomycin should be 6 weeks prior to initiation of study treatment), radiotherapy, molecular targeted therapy or other investigational drugs received in previous clinical trial =4 weeks; endocrine therapy =2 weeks or =5-half-life (whichever is shorter) prior to initiation of study treatment.

8. Major surgery within 4 weeks of the first dose of study drug and all surgical wounds must be healed and free of infection or dehiscence.

9. Vaccination with a live, attenuated vaccine within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivate vaccines (e.g., COVID-19 vaccines, inactivated influenza vaccines).

10. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade =1 severity (CTCAE v5.0) with the exception of alopecia, vitiligo or event(s) that is considered non-clinical meaningful by the Investigator.

11. History of Grade =3 immune-related adverse event(s) occurred in previous treatment.

12. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial (patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study; patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using MRI; the use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.

13. For expansion part only: last treatment with therapeutic oral or intravenous antibiotics within 2 weeks prior to first dose of study treatment.

14. Concomitant use of the drugs/remedies that may cause pharmacokinetic drug-drug interactions; Consumption of grapefruit juice, grapefruit hybrids, pomegranates, starfruit, pomelos, Seville oranges or juice or products within 7 days prior to the first dose of study medication (for Escalation Part only).

15. Active central nervous system (CNS) metastases including cerebral edema, system hormone treatment, disease progression due to intracranial lesions, leptomeningeal metastasis, and other clinical symptoms related to CNS metastases (if stable disease>8 weeks after treatment and free from glucocorticoids can be enrolled).

16. Impaired cardiac function or clinically significant cardiac disease, including any one

of the following:

• New York Heart Association class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiacarrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
• Baseline prolongation of the rate-corrected QT interval based on repeated demonstration of QTcF >480 ms or history of long QT interval corrected (QTc) syndrome (Note: QTc interval corrected by Fridericia's formula). Left ventricular ejection fraction (LVEF) <50% or below the lower limit of normal(whichever is higher)

17. Known human immunodeficiency virus or active hepatitis B, or active hepatitis C infection or active tuberculosis. Positive tests for hepatitis B virus surface antigen (HBsAg), or antibody to hepatitis B core Ag or hepatitis C RNA in serum. (subjects with history of hepatitis C infection but negative hepatitis C virus polymerase chain reaction (PCR) test and subjects with hepatitis B with positive hepatitis B surface antibody are allowed)

18. Patients with refractory/uncontrolled ascites or pleural effusion. Patients with indwelling catheters are allowed.

19. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test within 7 days prior to the start of study drug.

20. Non-surgically sterilized male or female patients of childbearing potential must agree to use effective methods of birth control during the study and for up to 6 months after the last dose of study drug.

21. Sexually active males unless they use a condom during intercourse while taking drug and for 5 compound half-lives plus 60 days after stopping study drug and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.

22. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• ABSK043 oral capsule
ABSK043 is a novel, oral small molecule inhibitor of PD-L1

Locations

Country	Name	City	State
Australia	Icon Cancer Centre South Brisbane	Brisbane	Queensland
Australia	Peninsula & South Eastern Haematology and Oncology Group	Frankston	Victoria
Australia	Sydney South West Private Hospital	Liverpool

Sponsors (1)

Lead Sponsor	Collaborator
Abbisko Therapeutics Co, Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	surface PD-L1 expression	Programmed death-ligand 1	Time Frame:at the end of Cycle 1 Day15 (each cycle is 28 days)
Other	metabolites of ABSK043	any major active metabolites	Time Frame: at the end of Cycle 1 Day15 (each cycle is 28 days)
Other	soluble PD-L1,	Programmed death-ligand 1	Time Frame:at the end of Cycle 1 Day15 (each cycle is 28 days)
Primary	DLT	dose-limiting toxicity	At the end of Cycle 1 (each cycle is 28 days)
Primary	Incidence and Severity of AEs	Adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)	Through study completion, an average of 6 months
Secondary	PFS	Progression-Free Survival	throughout study completion, on average of half year
Secondary	DCR	Disease control rate up to 24 weeks	throughout study completion, on average of half year
Secondary	DOR	Duration of response	throughout study completion, on average of half year
Secondary	Cmax	maximun observed concentration	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	Tmax	time to maximum observed concentration	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	AUC	area under the concentration-time curve	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	t1/2	half-life	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	Vz/F	apparent volume of distribution	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	CL/F	apparent oral clearance	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	Css_max	maximun observed concentration of steady-state	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	Css_min	minimum observed concentration of steady-state	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	AUCss	area under the concentration-time curve of steady-state	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	Rac	accumulation rate	at the end of Cycle 1 Day15 (each cycle is 28 days)
Secondary	ORR	Overall response rate	throughout study completion, on average of half year